MEDLINE Journals

    Third-generation bisphosphonates for treatment of sensorineural hearing loss in otosclerosis.

    Authors

    Quesnel AM, Seton M, Merchant SN, et al. 

    Institution

    Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts 02114, USA.

    Source

    Otol Neurotol 2012 Oct; 33(8) :1308-14.

    Abstract

    OBJECTIVE
    To evaluate hearing outcomes in patients treated with third generation bisphosphonates for otosclerosis-related sensorineural hearing loss (SNHL).
    HYPOTHESIS
    Otosclerosis is a disease of abnormal bone remodeling in the otic capsule. In recent years, third generation bisphosphonates, with more powerful anti-resorptive properties and increased bone affinity, have demonstrated effectiveness in the treatment of osteoporosis and other metabolic bone diseases. We hypothesized that newer generation bisphosphonates, such as risedronate and zoledronate, would be effective in slowing the progression of SNHL in patients with otosclerosis.
    STUDY DESIGN
    Retrospective review.
    SETTING
    Tertiary referral center, ambulatory care.
    INTERVENTIONS
    Risedronate or zoledronate administration.
    MAIN OUTCOME MEASURES
    Bone conduction pure tone threshold averages (PTAs) and word recognition (WR) scores were examined for each ear before and after bisphosphonate treatment. Criteria for significant change were defined as greater than 10 decibels in PTA or between 4% and 18% in WR based on binomial variance.
    RESULTS
    All 10 patients had audiometric progression of SNHL in the pretreatment monitoring interval and 12 ears met criteria for significant progression. All 10 patients (19 ears) showed at least no significant progression of SNHL (i.e., stabilization) at an average follow-up of 13 months. Two patients (3 ears) showed improvement by defined audiometric criteria. There were no major complications.
    CONCLUSION
    Treatment with zoledronate or risedronate stabilized progressive SNHL related to otosclerosis in this small group of patients. Further evaluation of third-generation bisphosphonate treatments is warranted.

    Mesh

    Adult
    Aged
    Audiometry, Pure-Tone
    Auditory Threshold
    Bone Conduction
    Bone Density Conservation Agents
    Diphosphonates
    Etidronic Acid
    Female
    Hearing Loss, Sensorineural
    Humans
    Imidazoles
    Male
    Middle Aged
    Otosclerosis
    Retrospective Studies
    Speech Perception
    Tomography, X-Ray Computed
    Treatment Outcome

    Language

    eng

    Pub Type(s)

    Journal Article Research Support, N.I.H., Extramural

    PubMed ID

    22935809

    Content Manager
    Related Content

    Re: Third-generation bisphosphonates for treatment of sensorineural hearing loss in otosclerosis, Otology & Neurotology 33:1308-1314, 2012.

    Medical treatment of otosclerosis: rationale for use of bisphosphonates.

    Audiometric analyses confirm a cochlear component, disproportional to age, in stapedial otosclerosis.

    Fluoride therapy for cochlear otosclerosis? an audiometric and computerized tomography evaluation.

    Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy.

    Surgical findings and long-term hearing results in 3,050 stapedotomies for primary otosclerosis: a prospective study with the otology-neurotology database.

    Stapedectomy for far-advanced otosclerosis.

    Hearing outcomes after surgical plugging of the superior semicircular canal by a middle cranial fossa approach.